Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2
Circulation · 08.07.2025 · 152 (1) · 27-40
DOI: 10.1161/circulationaha.125.074485 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Circulation, erschienen am 08.07.2025. Verfasst von Vivek Y Reddy und 27 weiteren Autor:innen. Beteiligte Einrichtung: Helmsley Electrophysiology Center, Mount Sinai Fuster Heart Hospital, New York, NY (V.Y.R., M.K.T.). Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Electrocardiography, Electrocardiography, Ambulatory. Die Arbeit wurde bisher 113-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boston Scientific Corporation.
Abstract (Originalsprache)
BACKGROUND: There are sparse high-quality safety and effectiveness data for pulsed field ablation (PFA) of persistent atrial fibrillation (PerAF), in which lesions beyond pulmonary vein isolation (PVI) are often placed. In addition, no large trials have used insertable cardiac monitors for continuous rhythm monitoring after ablation in patients with PerAF or after PFA in any atrial fibrillation population. In Phase 2 of the ADVANTAGE AF study (A Prospective Single Arm Open Label Study of the FARAPULSE Pulsed Field Ablation System in Subjects With Persistent Atrial Fibrillation), patients with PerAF underwent PFA for PVI and posterior wall ablation (PWA) and, in a subcohort, cavotricuspid isthmus ablation for typical atrial flutter. METHODS: Patients with PerAF underwent PVI and posterior wall ablation with the pentaspline PFA catheter and cavotricuspid isthmus with a novel focal-linear PFA catheter after intravenous nitroglycerin prophylaxis. Patients were followed up for 1 year with continuous rhythm monitoring after ablation with insertable cardiac monitors to emulate traditional intermittent monitoring for the primary efficacy end point and to examine atrial arrhythmia (AA) burden and episode duration. RESULTS: This 255-patient cohort (age, 66.7±9.3 years; female, 29%; CHA 2 DS 2 -VASc score, 2.4±1.4; body mass index, 30.9±5.3 kg/m 2 ; left atrium diameter, 4.3±0.6 cm) underwent PVI plus posterior wall ablation (99.6%/100% acute success); a subpopulation (n=141; 55.3%) also received cavotricuspid isthmus PFA, with 98.6% achieving bidirectional block without complications (ST-segment changes, ventricular fibrillation). Cavotricuspid isthmus ablation took 8±13 minutes, using 18±6 pulsed field applications and 4±2 mg IV nitroglycerin. The total procedure and atrial dwell times were 105±36 and 59±24 minutes, respectively. Mimicking traditional monitoring, freedom from AA was 73.4% with adverse events in 2.4%, both meeting prespecified end-point criteria. Freedom from recurrent atrial flutter was 97.2%. Detailed analysis of the full insertable cardiac monitor data revealed freedom from AA of ≥30 seconds in 52.0%, and no episode exceeded 24 hours in 94.0% of this PerAF cohort. Both an AA burden >0.1% and longest episode duration >1 hour were predictive of increased health care use. One-year procedural effectiveness was 71.6% and 70.0% using the thresholds of ≤0.1% burden and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Helmsley Electrophysiology Center, Mount Sinai Fuster Heart Hospital, New York, NY (V.Y.R., M.K.T.).
- University of California San Francisco (E.P.G.).
- Cardioangiologisches Centrum Bethanien, Frankfurt, Germany (B.S.).
- MercyOne Iowa Heart Center, West Des Moines (T.H.).
- St. Bernards Medical Center and Arrhythmia Research Group, Jonesboro, AR (D.N.).
- Texas Cardiac Arrhythmia Research, Austin (A.N.).
ORCID-Profile: Vivek Y Reddy, Edward P Gerstenfeld, Boris Schmidt, Jason G Andrade, Devi Nair, Andrea Natale, Walid Saliba, Philipp Sommer, Atul Verma, Troy Hounshell, Mohit K Turagam, Chinmay Patel, Ziad Issa, Allison M Anderson, Jonathan D Raybuck, Moussa Mansour
Förderung
- Boston Scientific Corporation
Zitieren
APA
Reddy, V. Y., Gerstenfeld, E. P., Schmidt, B., Andrade, J. G., Nair, D., Natale, A., Saliba, W., Sommer, P., Metzner, A., Verma, A., Hounshell, T., Amin, A., Gentlesk, P., Weiner, S., Cuoco, F. A., Kim, J., Turagam, M. K., Tomassoni, G., Patel, C., …, & ADVANTAGE AF Investigators (2025). Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2. Circulation, 152(1), 27-40. https://doi.org/10.1161/circulationaha.125.074485
Vancouver
Reddy VY, Gerstenfeld EP, Schmidt B, Andrade JG, Nair D, Natale A, et al. Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2. Circulation. 2025;152(1):27-40. doi:10.1161/circulationaha.125.074485
BibTeX
@article{Reddy2025,
author = {Reddy, Vivek Y and Gerstenfeld, Edward P and Schmidt, Boris and Andrade, Jason G and Nair, Devi and Natale, Andrea and Saliba, Walid and Sommer, Philipp and Metzner, Andreas and Verma, Atul and Hounshell, Troy and Amin, Anish and Gentlesk, Philip and Weiner, Stanislav and Cuoco, Frank A and Kim, Jamie and Turagam, Mohit K and Tomassoni, Gery and Patel, Chinmay and Issa, Ziad and Shehata, Michael and Anderson, Allison M and Stoltz, Thomas J and Raybuck, Jonathan D and Schwartz, Torri and Sutton, Brad S and Mansour, Moussa and ADVANTAGE AF Investigators, ADVANTAGE AF Investigators},
title = {Pulsed Field Ablation of Persistent Atrial Fibrillation With Continuous Electrocardiographic Monitoring Follow-Up: ADVANTAGE AF Phase 2},
journal = {Circulation},
year = {2025},
volume = {152},
number = {1},
pages = {27--40},
doi = {10.1161/circulationaha.125.074485}
}
EUVIMED